The Claim
Empagliflozin treatment for 8 weeks in obese mice on a high-fat diet shifts macrophage polarization in adipose tissue and liver from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, resulting in reduced tissue inflammation and lower systemic cytokine levels.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice fed a high-fat diet, an 8-week course of empagliflozin changes the type of immune cells in fat and liver tissue from inflammatory to anti-inflammatory, leading to decreased inflammation and lower levels of inflammatory signaling molecules in the blood.
See the scientific wording
In obese mice on a high-fat diet, empagliflozin treatment for 8 weeks shifted macrophage polarization in adipose tissue and liver from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, reducing tissue inflammation and systemic cytokine levels.
When empagliflozin blocks glucose reabsorption in the kidneys, the body starts burning more fat for energy. This change stresses fat cells, causing them to produce heat instead of storing fat. At the same time, immune cells in fat and liver switch from a harmful, inflammatory state to a healing, anti-inflammatory state. These healing immune cells release signals that further activate fat cells to burn energy and reduce overall inflammation in the body, lowering harmful chemicals in the blood.
What the research says
1 studyIn obese mice, a diabetes drug called empagliflozin helped change harmful immune cells in fat and liver into helpful ones, which lowered overall inflammation in the body.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.